

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinopharm Tech Holdings Limited

國藥科技股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 8156)

POSITIVE PROFIT ALERT

This announcement is made by Sinopharm Tech Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 17.10 of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to inform the shareholders and potential investors of the Company that, based on information that is currently available to the management of the Company and the preliminary review of the Group’s unaudited consolidated management accounts, the Group expects to record a profit attributable to equity holders of the Company of not less than HK\$9.0 million for the nine months ended 31 March 2023, as compared with a loss attributable to equity holders of the Company of approximately HK\$23.4 million for the corresponding period in 2022. The Board believes such turnaround from loss to profit is mainly attributable to, among other things, (i) strengthened cost control on administrative and operating expenses; (ii) compensation income from sales of locked-up consideration shares amounted to approximately HK\$16.5 million which was recorded as other income; and (iii) gain on settlement of amount due to an ex-Director amounted to approximately HK\$12.6 million which was recorded as other income.

The Company is in the process of finalising the unaudited consolidated results of the Group for the nine months ended 31 March 2023. Information contained in this announcement is compiled based on the preliminary assessment by the management of the Company on the unaudited consolidated management accounts of the Group for the nine months ended 31 March 2023 only and not based on any figures or information which have been audited or reviewed by the Company’s auditors. The unaudited consolidated results of the Group for the nine months ended 31 March 2023 are expected to be announced on 15 May 2023.

The shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Sinopharm Tech Holdings Limited
國藥科技股份有限公司
CHAU Wai Wah Fred
Executive Director

Hong Kong, 8 May 2023

As at the date of this announcement, the Board comprises Mr. CHAU Wai Wah Fred, Mr. HO Kam Kin and Ms. KWOK Shuk Yi as executive Directors, Dr. CHENG Yanjie as non-executive Director and Mr. LAU Fai Lawrence, Dr. LIU Ta-pei and Mr. LAM Kit Sun as independent non-executive Directors.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Listed Company Information” page of the GEM website at www.hkexnews.hk for a minimum period of 7 days from the date of its publication and on the website of the Company at www.sinopharmtech.com.hk.